Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT06692270 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06692270
- Sponsor
- Fujian Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-15
- Primary completion
- 2026-01-10
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.